Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies

Immunotherapy, especially based on chimeric antigen receptor (CAR) T cells, has achieved prominent success in the treatment of hematological malignancies. However, approximately 30-50% of patients will have disease relapse following remission after receiving CD19-targeting CAR-T cells, with failure...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Chunyi, Zhang, Zhen, Zhang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603553/
https://www.ncbi.nlm.nih.gov/pubmed/33150182
http://dx.doi.org/10.1155/2020/8765028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603553/
https://www.ncbi.nlm.nih.gov/pubmed/33150182
http://dx.doi.org/10.1155/2020/8765028

Ejemplares similares